medigraphic.com
ISSN 2448-8909 (Impreso)

2017, Número 3

<< Anterior Siguiente >>

Med Crit 2017; 31 (3)


Infección por Fusarium en el paciente quemado. A propósito de cuatro casos

Carrillo ER, Taméz CA, Garnica EMA, López JLE, Carrillo CJR, Osegueda EJ

Idioma: Español
Referencias bibliográficas: 35
Paginas: 159-163
Archivo PDF: 182.93 Kb.


RESUMEN

Las quemaduras son un problema de salud pública y una de las presentaciones más graves del trauma. Los avances en el manejo del enfermo quemado grave han mejorado de manera significativa su supervivencia, lo que también ha condicionado un incremento en el riesgo y el número de infecciones micóticas. Las infecciones micóticas en el quemado se pueden presentar de manera aislada o asociadas a infección polimicrobiana. Fusarium es una especie fúngica ubicua que puede causar en el humano infecciones graves. Su principal forma de presentación clínica es la cutánea o superficial, pero en pacientes inmunocomprometidos, de los que destacan los enfermos con quemaduras graves, puede diseminarse y condicionar infección a diferentes órganos. El objetivo de este trabajo es describir la epidemiología, manifestaciones clínicas y desenlace de una serie de enfermos quemados graves que presentó infección por Fusarium spp.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917.

  2. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7(4):479-504.

  3. Cho CT, Vats TS, Lowman JT, Brandsberg JW, Tosh FE. Fusarium solani infection during treatment of acute leukemia. J Pediatr, 1973;83(6):1028-1031.

  4. Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol. 1981;75(3):304-311.

  5. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403-434.

  6. Shankar R, Melstrom KA Jr, Gamelli RL. Inflammation and sepsis: past, present, and the future. J Burn Care Res. 2007;28(4):566-571.

  7. Ha JF, Italiano CM, Heath CH, Shih S, Rea S, Wood FM. Candidemia and invasive candidiasis: a review of the literature for the burns surgeon. Burns. 2011;37(2):181-195.

  8. Murray CK, Loo FL, Hospenthal DR, Cancio LC, Jones JA, Kim SH, et al. Incidence of systemic fungal infection and related mortality following severe burns. Burns. 2008;34(8):1108-1112.

  9. Horvath EE, Murray CK, Vaughan GM, Chung KK, Hospenthal DR, Wade CE, et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Ann Surg. 2007;245(6):978-985.

  10. Stone HH, Cuzzell JZ, Kolb LD, Moskowitz MS, McGowan JE Jr. Aspergillus infection of the burn wound. J Trauma. 1979;19(10):765-767.

  11. Nir-Paz R, Strahilevitz J, Shapiro M, Keller N, Goldschmied-Reouven A, Yarden O, et al. Clinical and epidemiological aspects of infections caused by Fusarium species: a collaborative study from Israel. J Clin Microbiol. 2004;42(8):3456-3461.

  12. Struck MF, Gille J. Fungal infections in burns: a comprehensive review. Ann Burns Fire Disasters. 2013;26(3):147-153.

  13. Moore EC, Padiglione AA, Wasiak J, Paul E, Cleland H. Candida in burns: risk factors and outcomes. J Burn Care Res. 2010;31(2):257-263.

  14. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules. 2014;19(1):1085-1119.

  15. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695-704.

  16. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004;10 Suppl 1:67-75.

  17. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92(6):305-316.

  18. Schaal JV, Leclerc T, Soler C, Donat N, Cirrode A, Jault P, et al. Epidemiology of filamentous fungal infections in burned patients: A French retrospective study. Burns. 2015;41(4):853-863.

  19. Rosanova MT, Brizuela M, Villasboas M, Guarracino F, Alvarez V, Santos P, et al. Fusarium spp. infections in a pediatric burn unit: nine years of experience. Braz J Infect Dis. 2016;20(4):389-392.

  20. Nucci M, Carlesse F, Cappellano P, Varon AG, Seber A, Garnica M, et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One. 2014;9(1):e87784.

  21. Marinach-Patrice C, Lethuillier A, Marly A, Brossas JY, Gené J, Symoens F, et al. Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect. 2009;15(7):634-642.

  22. Landlinger C, Preuner S, Willinger B, Haberpursch B, Racil Z, Mayer J, et al. Species-specific identification of a wide range of clinically relevant fungal pathogens by use of Luminex xMAP technology. J Clin Microbiol. 2009;47(4):1063-1073.

  23. Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol. 2009;47(4):877-884.

  24. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother. 2002;46(7):2273-2275.

  25. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383-1396.

  26. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41(10):4898-900.

  27. Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032-1037.

  28. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122-1131.

  29. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42(10):1398-1403.

  30. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775-785.

  31. Spellberg B, Schwartz J, Fu Y, Avanesian V, Adler-Moore J, Edwards JE Jr, et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother. 2006;58(5):973-979.

  32. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag. 2007;3(6):1165-1173.

  33. Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365-1366.

  34. Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis. 1995;14(8):697-699.

  35. Muhammed M, Coleman JJ, Carneiro HA, Mylonakis E. The challenge of managing fusariosis. Virulence. 2011;2(2):91-96.




2020     |     www.medigraphic.com